What was the overall market valuation of the US gingivostomatitis market in 2024?

The overall market valuation was $189.0 Million in 2024. Read More

What is the projected market valuation for the US gingivostomatitis market by 2035?

The projected valuation for 2035 is $318.0 Million. Read More

What is the expected CAGR for the US gingivostomatitis market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 4.84%. Read More

What were the market valuations for different types of gingivostomatitis in 2024?

In 2024, the market valuations were $75.0 Million for Viral, $60.0 Million for Bacterial, and $54.0 Million for Fungal types. Read More

How do the symptoms of gingivostomatitis break down in terms of market valuation?

In 2024, the market valuations for symptoms were $40.0 Million for Pain, $30.0 Million for Sores, $25.0 Million for Swelling, $20.0 Million for Fever, and $14.0 Million for Bad Breath. Read More

What treatment methods are utilized in the US gingivostomatitis market and their valuations?

In 2024, treatment method valuations were $30.0 Million for Topical, $50.0 Million for Systemic, and $109.0 Million for Supportive Care. Read More

What is the market segmentation by age group for gingivostomatitis?

In 2024, the market segmentation by age group showed $100.0 Million for Adults, $30.0 Million for Pediatrics, and $59.0 Million for Geriatrics. Read More

How does the market for gingivostomatitis appear to be evolving towards 2035?

The market appears to be evolving positively, with a projected increase to $318.0 Million by 2035. Read More

What trends might influence the growth of the US gingivostomatitis market in the coming years?

Trends such as increased awareness, advancements in treatment methods, and a growing geriatric population may influence market growth. Read More

US Gingivostomatitis Market

Q: Which companies are considered key players in the US gingivostomatitis market?

Key players include GlaxoSmithKline, Pfizer, Johnson & Johnson, Bristol-Myers Squibb, Merck & Co., Sanofi, AstraZeneca, and Novartis. Read More

ID: MRFR/Pharma/18399-HCR 100 Pages Satyendra Maurya Last Updated: September 10, 2026

US Gingivostomatitis Market Research Report By Type (Viral, Bacterial, Fungal), By Symptoms (Sores, Swelling, Fever, Pain, Bad Breath), By Treatment Method (Topical, Systemic, Supportive Care) and By Age Group (Pediatric, Adult, Geriatric) - Growth & Industry Forecast 2025 To 2035

US Gingivostomatitis Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)4.84%

2024 Market Size$ 189 Million

2025 Market Size$ 198.15 Million

2035 Market Size$ 318 Million

Key Players

GlaxoSmithKline

Pfizer

Johnson & Johnson

Bristol-Myers Squibb

Merck & Co.

Sanofi

Trends

Rising Awareness of Oral Health
Technological Advancements in Treatment
Research and Development of Targeted Therapies

Opportunities

Expansion of Dental Care Services
Rising Demand for Preventive Care
Advancements in Treatment Modalities

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Food, Beverages & Nutrition, BY Type (USD Million)
  1. 4.1.1 Viral
  2. 4.1.2 Bacterial
  3. 4.1.3 Fungal
2. 4.2 Food, Beverages & Nutrition, BY Symptoms (USD Million)
  1. 4.2.1 Sores
  2. 4.2.2 Swelling
  3. 4.2.3 Fever
  4. 4.2.4 Pain
  5. 4.2.5 Bad Breath
3. 4.3 Food, Beverages & Nutrition, BY Treatment Method (USD Million)
  1. 4.3.1 Topical
  2. 4.3.2 Systemic
  3. 4.3.3 Supportive Care
4. 4.4 Food, Beverages & Nutrition, BY Age Group (USD Million)
  1. 4.4.1 Pediatric
  2. 4.4.2 Adult
  3. 4.4.3 Geriatric
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 GlaxoSmithKline (GB)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Pfizer (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Johnson & Johnson (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Bristol-Myers Squibb (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Merck & Co. (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Sanofi (FR)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 AstraZeneca (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Novartis (CH)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY SYMPTOMS
4. 6.4 US MARKET ANALYSIS BY TREATMENT METHOD
5. 6.5 US MARKET ANALYSIS BY AGE GROUP
6. 6.6 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
9. 6.9 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
10. 6.10 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
11. 6.11 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
12. 6.12 FOOD, BEVERAGES & NUTRITION, BY TYPE, 2024 (% SHARE)
13. 6.13 FOOD, BEVERAGES & NUTRITION, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 FOOD, BEVERAGES & NUTRITION, BY SYMPTOMS, 2024 (% SHARE)
15. 6.15 FOOD, BEVERAGES & NUTRITION, BY SYMPTOMS, 2024 TO 2035 (USD Million)
16. 6.16 FOOD, BEVERAGES & NUTRITION, BY TREATMENT METHOD, 2024 (% SHARE)
17. 6.17 FOOD, BEVERAGES & NUTRITION, BY TREATMENT METHOD, 2024 TO 2035 (USD Million)
18. 6.18 FOOD, BEVERAGES & NUTRITION, BY AGE GROUP, 2024 (% SHARE)
19. 6.19 FOOD, BEVERAGES & NUTRITION, BY AGE GROUP, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY SYMPTOMS, 2025-2035 (USD Million)
  3. 7.2.3 BY TREATMENT METHOD, 2025-2035 (USD Million)
  4. 7.2.4 BY AGE GROUP, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Enquiry

Customize Report

US Gingivostomatitis Market Segmentation

US Gingivostomatitis Market By Type (USD Million, 2025-2035)

Viral
Bacterial
Fungal

US Gingivostomatitis Market By Symptoms (USD Million, 2025-2035)

Sores
Swelling
Fever
Pain
Bad Breath

US Gingivostomatitis Market By Treatment Method (USD Million, 2025-2035)

Topical
Systemic
Supportive Care

US Gingivostomatitis Market By Age Group (USD Million, 2025-2035)

Pediatric
Adult
Geriatric

Certified Researchers

Enquiry

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”